Thus, our findings do not support a role for NF-κB activity as a significant mediator of gemcitabine resistance in pancreatic cancer, or the corollary that NF-κB inhibition is able to overcome chemotherapy resistance. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.